| Name | Title | Contact Details |
|---|
Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.
Rakuten Aspyrian, Inc is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany.
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).
Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.